Additional file 2 of Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions

Abstract

Additional file 2: Figure S1. Additional mean concentration–time profiles of ivermectin in cattle plasma. Figure S2. Kaplan-Meier plots. Figure S3. Four-day cumulative mortality of KIS and VK5. Figure S4. Heat maps illustrating the lower 95% confidence limit (LCL) of 4-day and 30-day mortality hazard ratios (HRs) for KIS and VK5 colony mosquitoes. Figure S5. Relationship between ivermectin plasma concentration and 4-day (A, B) or 10-day (C , D) cumulative mortality for each candidate formulation. Figure S6. Relationship between ivermectin plasma concentrations and 4-day cumulative mosquito mortality for KIS and VK5 colonies